CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aixcrypto Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aixcrypto Holdings Inc
5857 Owens Avenue
Phone: (760) 452-8111p:760 452-8111 CARLSBAD, CA  92008  United States Ticker: AIXCAIXC
This company was Merged or Acquired on 9/30/2025.
This is a Subsidiary, click here for the Parent Company
Business Summary
AIxCrypto Holdings, Inc., formerly Qualigen Therapeutics, Inc., is focused on building an ecosystem that integrates Artificial Intelligence (AI) and blockchain, bridging Web2 and Web3. This ecosystem unites a decentralized protocol, distributed network, AI DePIN and EAI RWA value regeneration, and a DeAI Agent product and technology platform designed to achieve optimal trading performance. Its core products include the BesTrade DeAI Agent and the AIxC ecosystem products. Its crypto business, CXC10, is centered on three growth engines which include six key products: C - Crypto 10 (C10) as Value Anchor, X - DeAI Agent, and C - RWA & Ecosystem Tokens. C - Crypto 10 (C10) as Value Anchor - through the C10 Digital Asset Treasury, C10 Index, and a potential C10 ETF. C - RWA & Ecosystem Tokens - including the C10 Stablecoin and the EAI + Crypto Dual-Bridge Real World Asset product, bridging traditional assets with Web3. It also develops and commercializes oncology and immunology therapies.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
7374 Computer processing and data preparation and processing services
7372 Prepackaged software
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board JaySheng 42 11/17/2025 9/29/2025
President CampbellBecher 53 9/29/2025 7/5/2024
Co-Chief Executive Officer, Director KevinRichardson 57 10/2/2025 9/26/2024
4 additional Officers and Directors records available in full report.

Business Names
Business Name
AIXC
NanoSynex Ltd.
QLGN
Qualigen, Inc.
Qualigen, Inc.
RTTR

General Information
Number of Employees: 4 (As of 3/25/2024)
Outstanding Shares: 5,160,383 (As of 11/14/2025)
Shareholders: 227
Stock Exchange: NASD
Federal Tax Id: 201295171
Fax Number: (310) 919-1600
Email Address: info@ritterpharma.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 24, 2025